Publications
Detailed Information
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rugo, Hope S. | - |
dc.contributor.author | Cortes, Javier | - |
dc.contributor.author | Awada, Ahmad | - |
dc.contributor.author | O'Shaughnessy, Joyce | - |
dc.contributor.author | Twelves, Chris | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Hannah, Alison | - |
dc.contributor.author | Lu, Lin | - |
dc.contributor.author | Sy, Sherwin | - |
dc.contributor.author | Caygill, Katie | - |
dc.contributor.author | Zajchowski, Deborah A. | - |
dc.contributor.author | Davis, Darren W. | - |
dc.contributor.author | Tagliaferri, Mary | - |
dc.contributor.author | Hoch, Ute | - |
dc.contributor.author | Perez, Edith A. | - |
dc.date.accessioned | 2022-03-22T09:07:18Z | - |
dc.date.available | 2022-03-22T09:07:18Z | - |
dc.date.created | 2019-06-27 | - |
dc.date.created | 2019-06-27 | - |
dc.date.issued | 2018-07 | - |
dc.identifier.citation | Clinical Cancer Research, Vol.24 No.14, pp.3348-3357 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.other | 76900 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177164 | - |
dc.description.abstract | Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP). Experimental Design: The BEACON trial treated patients with metastatic breast cancer (MBC) with EP or treatment of physician's choice (TPC). Blood from 656 of 852 patients (77%) was processed with ApoStream to enrich for CTCs. A multiplex immunofluorescence assay measured expression of candidate response biomarkers [topoisomerase 1 (Top1), topoisomerase 2 (Top2), Ki67, RAD51, ABCG2, gamma H2AX, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)] in CTCs. Patients were classified as Top1 low (Top1Lo) or Top1 high (Top1Hi) based on median CTC Top1 expression. Correlation of CTC biomarker expression at baseline, cycle 2 day 1 (C2D1), and cycle 4 day 1 with overall survival (OS) was investigated using Cox regression and Kaplan-Meier analyses. Results: Overall, 98% of samples were successfully processed, of which 97% had detectable CTCs (median, 47-63 CTCs/mL; range, 0-2,020 CTCs/mL). Top1, Top2, and TUNEL expression was detected in 52% to 90% of samples; no significant associations with OS were observed in pretreatment samples for either group. EP-treated patients with low C2D1Top1(+) CTCs had improved OS compared with those with higher positivity (14.1 months vs. 11.0 months, respectively; HR, 0.7; P = 0.02); this difference was not seen in TPC-treated patients (HR, 1.12; P = 0.48). Patients whose CTCs decreased from Top1Hi to Top1Lo at C2D1 had the greatest OS benefit from EP (HR, 0.57; P = 0.01). Conclusions: CTC Top1 expression following EP treatment may identify patients withMBC most likely to have an OS benefit. (C) 2018 AACR. | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-17-3059 | - |
dc.citation.journaltitle | Clinical Cancer Research | - |
dc.identifier.wosid | 000439200800016 | - |
dc.identifier.scopusid | 2-s2.0-85050148315 | - |
dc.citation.endpage | 3357 | - |
dc.citation.number | 14 | - |
dc.citation.startpage | 3348 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000439200800016 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | I INHIBITORS | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | ANTHRACYCLINE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | THERAPY | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.